CERECIN
Cerecin is a healthcare company that develops novel evidence-based therapeutics and products that aim to help people. Cerecin develops novel evidence-based therapeutics and products that aim to help millions of people. These solutions are designed to target conditions ranging from memory impairment to Alzheimer’s disease and other devastating neurological diseases. The company was founded in 2001 and is based in Denver, Colorado.
CERECIN
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2001-01-01
Address:
Denver, Colorado, United States
Country:
United States
Website Url:
http://www.cerecin.com
Total Employee:
11+
Status:
Active
Contact:
+1 303 999 3700
Email Addresses:
[email protected]
Total Funding:
77.34 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics Font Awesome Global Site Tag
Current Advisors List
Current Employees Featured
Founder
Investors List
Medici Investment
Medici Investment investment in Series A - Cerecin
Partners Investment
Partners Investment investment in Series A - Cerecin
M Capital Partners
M Capital Partners investment in Series A - Cerecin
KB Financial Group
KB Financial Group investment in Series A - Cerecin
KT investment Inc.
KT investment Inc. investment in Series A - Cerecin
Hana Financial Investment
Hana Financial Investment investment in Series A - Cerecin
SK Securities
SK Securities investment in Series A - Cerecin
Shinhan Investment
Shinhan Investment investment in Series A - Cerecin
IBK Capital
IBK Capital investment in Series A - Cerecin
Arche Investment
Arche Investment investment in Series A - Cerecin
Official Site Inspections
http://www.cerecin.com Semrush global rank: 3.66 M Semrush visits lastest month: 3.86 K
- Host name: ec2-52-73-101-155.compute-1.amazonaws.com
- IP address: 52.73.101.155
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Cerecin"
Cerecin Neurosciences
Cerecin to Present New Infantile Spasms Data at the 35th Interna1onal Epilepsy Congress, Dublin 2023 . 30 August 2023. View More. Clinical Trial Data of Novel Metabolic Mechanism in …See details»
Cerecin Neurosciences
Cerecin pioneers the science of neuro-metabolism and ketogenic drug development. With a world-class team and strong strategic partners, Nestle and Wilmar, Cerecin has bold ambitions to develop a portfolio of first-in-class …See details»
Cerecin - Crunchbase Company Profile & Funding
Cerecin is a healthcare company that develops novel evidence-based therapeutics and products that aim to help people. Cerecin develops novel evidence-based therapeutics and products that aim to help millions of people. …See details»
Cerecin Neurosciences
World health organization estimates ~38 M patients of AD in the world in 2023 1, are expected to grow to 132M by 2050. ... Cerecin Pty. Ltd. 102 Fox Drive Dandenong 3175, Victoria, Australia [email protected]. Korea Cerecin Korea …See details»
Cerecin - LinkedIn
Cerecin | 5,659 followers on LinkedIn. Cerecin is a healthcare company with almost 20 years of innovation and leadership in brain health. | Cerecin is a global healthcare company with almost …See details»
Cerecin Company Profile 2024: Valuation, Funding & Investors
Cerecin General Information Description. Developer of therapeutics technology designed to treat memory impairment and other neurodegenerative diseases. The company offers lipid science …See details»
Cerecin Company Profile - Office Locations, Competitors ... - Craft
Cerecin has 5 employees across 3 locations. See insights on Cerecin including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Cerecin received US FDA clearance to study CER-0001 under
Dec 7, 2022 Cerecin is supported by two multinational partners, Nestlé S.A. (NSRGY), and Wilmar International Limited (F34.SI), as well as a syndicate of leading institutional investors. …See details»
Cerecin raises $40 Million Series II and IIA financing to support its ...
DENVER and SINGAPORE, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced it has …See details»
Cerecin strengthens position in neurometabolism with addition to …
Sep 19, 2023 Cerecin undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by …See details»
Cerecin Neurosciences
Cerecin is investigating whether tricaprilin, through exogenous induction of ketone bodies, can provide an alternative fuel source for these metabolically compromised areas of the brain. …See details»
Cerecin forges strategic partnership with A*STAR's Institute of ...
Dec 1, 2023 Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of …See details»
Cerecin Announces Orphan Drug Designation from U.S. FDA for
Oct 29, 2020 Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and is supported by two corporate …See details»
Cerecin raises $40 Million Series II and IIA financing to
Oct 19, 2021 Cerecin is led by an executive management team with global expertise in central nervous system drug development. Cerecin is supported by two partners, Nestlé, and Wilmar, …See details»
Cerecin closes Series IIB financing to advance CER-0001 clinical ...
Sep 28, 2022 Cerecin. Series IIB Financing was supported by existing and new investors in South Korea. Proceeds strengthen Cerecin’s operating position to advance the clinical studies …See details»
Cerecin Neurosciences
Cerecin has developed a novel, proprietary technology and method of synthesis which results in an ultrapure version of tricaprilin. Ultrapure tricaprilin contains low levels of impurities …See details»
Cerecin Neurosciences
Cerecin Announces Abstract on New Infantile Spasms Data Accepted for Oral Presentation at the International League Against Epilepsy EME Congress 2022. 31 October 2022. Results of Pilot …See details»
Cerecin closes Series IIB financing to advance CER-0001
Sep 28, 2022 Cerecin is on the right path.” Cerecin closed a USD $40 million Series II and IIA Round in the 4 th quarter of 2021 following a cornerstone investment made by long-term …See details»
Cerecin Enrolls First Patient in a Pilot Clinical Trial of
Nov 9, 2021 Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and is supported by two partners, …See details»
Results of Pilot Study of CER-0001 in Migraine support
Oct 31, 2022 Cerecin has received authorization from the U.S. Food and Drug Administration (FDA) to study CER-0001 in migraine under an Investigational New Drug (IND) application. …See details»